Digital Biomarkers (Nov 2020)

A Roadmap to Inform Development, Validation and Approval of Digital Mobility Outcomes: The Mobilise-D Approach

  • Lynn Rochester,
  • Claudia Mazzà,
  • Arne Mueller,
  • Brian Caulfield,
  • Marie McCarthy,
  • Clemens Becker,
  • Ram Miller,
  • Paolo Piraino,
  • Marco Viceconti,
  • Wilhelmus P. Dartee,
  • Judith Garcia-Aymerich,
  • Aida A. Aydemir,
  • Beatrix Vereijken,
  • Valdo Arnera,
  • Nadir Ammour,
  • Michael Jackson,
  • Tilo Hache,
  • Ronenn Roubenoff

DOI
https://doi.org/10.1159/000512513
Journal volume & issue
Vol. 4, no. 1
pp. 13 – 27

Abstract

Read online

Health care has had to adapt rapidly to COVID-19, and this in turn has highlighted a pressing need for tools to facilitate remote visits and monitoring. Digital health technology, including body-worn devices, offers a solution using digital outcomes to measure and monitor disease status and provide outcomes meaningful to both patients and health care professionals. Remote monitoring of physical mobility is a prime example, because mobility is among the most advanced modalities that can be assessed digitally and remotely. Loss of mobility is also an important feature of many health conditions, providing a read-out of health as well as a target for intervention. Real-world, continuous digital measures of mobility (digital mobility outcomes or DMOs) provide an opportunity for novel insights into health care conditions complementing existing mobility measures. Accepted and approved DMOs are not yet widely available. The need for large collaborative efforts to tackle the critical steps to adoption is widely recognised. Mobilise-D is an example. It is a multidisciplinary consortium of 34 institutions from academia and industry funded through the European Innovative Medicines Initiative 2 Joint Undertaking. Members of Mobilise-D are collaborating to address the critical steps for DMOs to be adopted in clinical trials and ultimately health care. To achieve this, the consortium has developed a roadmap to inform the development, validation and approval of DMOs in Parkinson’s disease, multiple sclerosis, chronic obstructive pulmonary disease and recovery from proximal femoral fracture. Here we aim to describe the proposed approach and provide a high-level view of the ongoing and planned work of the Mobilise-D consortium. Ultimately, Mobilise-D aims to stimulate widespread adoption of DMOs through the provision of device agnostic software, standards and robust validation in order to bring digital outcomes from concept to use in clinical trials and health care.

Keywords